'Boring' Bodes Well For Future Of Intercept's Ocaliva
This article was originally published in Scrip
There was nothing to be shocked about in the FDA's briefing documents released ahead of its April 7 meeting of its Gastrointestinal Drugs Advisory Committee (GDAC) for Intercept Pharmaceuticals Inc.'s obeticholic acid (OCA), a new molecular entity the company is seeking to market as Ocaliva to treat primary biliary cirrhosis (PBC), a rare and potentially fatal liver disease.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.